Suzhou Basecare Medical Full Year 2024 Earnings: CN¥0.90 loss per share (vs CN¥0.70 loss in FY 2023)

Simply Wall St

March 31, 2025

Suzhou Basecare Medical (HKG:2170) Full Year 2024 Results

Key Financial Results

Revenue: CN¥299.1m (up 44% from FY 2023).
Net loss: CN¥237.0m (loss widened by 24% from FY 2023).
CN¥0.90 loss per share (further deteriorated from CN¥0.70 loss in FY 2023).

The end of cancer? These 15 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.

earnings-and-revenue-history — SEHK:2170 Earnings and Revenue History March 31st 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Suzhou Basecare Medical shares are down 3.9% from a week ago.

Risk Analysis

We don't want to rain on the parade too much, but we did also find 1 warning sign for Suzhou Basecare Medical that you need to be mindful of.

If you're looking to trade Suzhou Basecare Medical, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.

With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.

Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.